Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation.

Journal of the American Heart Association·2022
Same author

Catheter ablation of atrial fibrillation in patients with cor triatriatum sinister; case series and review of literature.

Pacing and clinical electrophysiology : PACE·2021
Same author

Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early Recurrence.

Journal of thoracic imaging·2019
Same journal

Sweating the Details: A Reflective Pause in our Procedural Workflow.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale and Atrial Septal Defect.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale Embryology, Anatomy, and Physiology.

Cardiac electrophysiology clinics·2026
Same journal

Management of Arrhythmias in the Cardiovascular Intensive Care Unit.

Cardiac electrophysiology clinics·2026
Same journal

Left Ventricular Assist Device Emergencies: Diagnosis and Management.

Cardiac electrophysiology clinics·2026
Same journal

Advanced Critical Care Techniques in the Field.

Cardiac electrophysiology clinics·2026
See all related articles

Related Experiment Videos

Sotalol.

John Alvin Kpaeyeh1, John Marcus Wharton2

  • 1Division of Cardiology, Department of Medicine, Tourville Arrhythmia Center, Medical University of South Carolina, 114 Doughty Street, MSC 592, Charleston, SC 29425-5920, USA.

Cardiac Electrophysiology Clinics
|June 5, 2016
PubMed
Summary
This summary is machine-generated.

Sotalol effectively treats various heart rhythm disorders by affecting potassium channels. However, low doses did not outperform placebo for atrial fibrillation, and caution is advised with interacting medications.

Keywords:
Atrial fibrillationLong QT syndromePotassium channel blockerSotalolVentricular tachycardia

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Sotalol is a recognized antiarrhythmic medication.
  • Its mechanism involves blocking potassium channels, impacting cardiac repolarization.
  • Effective in treating atrial fibrillation (AF) and ventricular arrhythmias.

Purpose of the Study:

  • To evaluate the efficacy of sotalol in treating cardiac arrhythmias.
  • To understand the dose-response relationship and drug interactions of sotalol.

Main Methods:

  • Review of clinical trials and pharmacological data.
  • Analysis of sotalol's effect on the QT interval and its bioavailability.
  • Assessment of drug interactions with medications causing QT prolongation, bradycardia, or hypotension.

Main Results:

  • Sotalol demonstrates efficacy in treating supraventricular and ventricular tachycardias.
  • A linear correlation exists between sotalol dosage and QT interval prolongation.
  • Low-dose sotalol showed no significant benefit over placebo in AF patients.
  • Oral sotalol exhibits near 100% bioavailability.

Conclusions:

  • Sotalol is a valuable antiarrhythmic agent for specific conditions.
  • Dosage titration is crucial, with careful consideration of QT prolongation.
  • Concomitant use with drugs prolonging QT, causing bradycardia, or hypotension should be avoided.